Cytori Therapeutics (NASDAQ:CYTX) Stock Passes Above 50-Day Moving Average of $0.25

Cytori Therapeutics Inc (NASDAQ:CYTX)’s share price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.25 and traded as high as $0.23. Cytori Therapeutics shares last traded at $0.23, with a volume of 16,348 shares.

Several research firms have recently commented on CYTX. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Maxim Group reiterated a “hold” rating on shares of Cytori Therapeutics in a report on Monday, April 1st.

The stock has a fifty day simple moving average of $0.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.30 and a current ratio of 0.46.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%. The business had revenue of $0.70 million for the quarter.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Barclays PLC grew its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 724.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 99,747 shares of the biotechnology company’s stock after purchasing an additional 87,647 shares during the quarter. Barclays PLC owned approximately 0.76% of Cytori Therapeutics worth $29,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.62% of the company’s stock.

Cytori Therapeutics Company Profile (NASDAQ:CYTX)

Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.

Featured Article: Front-End Load

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.